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EDITORIAL
Treatment of end-stage renal disease (ESRD) in South Africa is
an important public health issue. The prevalence of ESRD in
South Africa is unknown. Data from Europe and the USA
estimate the prevalence to be 790 and 1 400 per million
population respectively.1 The prevalence figures from the USA
indicate a marked increase in the incidence of chronic renal
failure (CRF) in the African American population,
approximately fourfold greater than for the Caucasian
American population, and thus the figures in South Africa are
likely to approximate or exceed the US data. It is estimated
from the Southern Africa Dialysis and Transplantation Registry
that only about 99 cases per million population receive
treatment.2 There is therefore a huge shortfall of facilities to
treat ESRD, and it is important to optimise treatment for ESRD
in South Africa within the budgetary restrictions. Dialysis is
not the solution. It is very expensive and offers treatment to
only a small number of patients due to limited facilities and
expense. Transplantation, on the other hand, is cost effective in
the long term, offers the chance of full rehabilitation and can be
offered to a greater number of patients provided that there is a
sufficient supply of organs. Dialysis should only be seen as a
staging procedure to transplantation in South Africa.
The National Department of Health (DOH) has produced
guidelines for the provision of dialysis and transplantation,
emphasising the following points. Firstly, there must be
equitable access to treatment for all who require it. Secondly,
the provision of dialysis and transplantation is very costly and
therefore treatment for all is currently unaffordable.
Consequently some degree of selection is needed. The DOH
has indicated in the guidelines that the following
considerations are the most important in selecting patients for
treatment: (i) suitability for transplantation; ( ii) age less than 65
years; (iii) compliance with treatment; and (iv) absence of other
significant pathology that will interfere significantly with
treatment.
It is vital that the results of transplantation are documented
in South Africa to ensure optimal use of scarce resources. Most
studies have originated from Europe or the USA. The Southern
Africa Dialysis and Transplantation Registry has documented
dialysis and transplant outcomes in South Africa, but the last
reliable report was issued in 1994.2 It is therefore timely that in
this issue of the Journal Moosa presents a paper documenting
the results of 542 patients receiving 623 cadaver transplants at
the renal unit, University of Stellenbosch and Tygerberg
Hospital from 1976 to 1999. 3 This is the first comprehensive
paper from a single South African centre analysing transplant
results over an extended period, and it focuses primarily on the
impact of age, gender and race. Previous studies have
suggested that older patients, blacks and women may have
poorer outcomes. The reasons for these different outcomes are
not entirely clear. It has been suggested that older people may
be more prone to complications of immunosuppression due to
declining immune function and altered drug  metabolism with
increased immunosuppression and susceptibility to infection.4,5
The impact of gender on patient survival is controversial.
Troppmann et al.6 and Gorlén et al.7 reported increased
mortality in women compared with men, but Arend and co-
workers8 reported a lower mortality rate. Possible explanations
for the higher mortality in women include the presence of
preformed cytotoxic antibodies from prior pregnancies
resulting in increased likelihood of rejection, and different
requirements with regard to immunosuppressive drugs. Blacks
may have poorer outcomes because of lower socioeconomic
conditions,9,10 less HLAmatching of organs10 and more severe
hypertension,11 which potentially impact on transplant
outcomes.
The issues of race, gender and age are particularly important
in South Africa for historical reasons. Blacks, women and the
elderly are often the most marginalised sectors of our society.
In addition the effects of immunosuppression on infectious
diseases such as tuberculosis (TB) are important issues in a
developing country.
The results of the paper presented by Moosa are relevant to
renal transplantation in South Africa. In essence the paper
found that there were no ethnic differences in outcome, but
there was increased mortality in women and patients older
than 40 years. Graft survival was good provided that it was
censored for patient mortality.
In contrast to a previous report from the Baragwanath
group12 the finding by Moosa that there were no ethnic
differences in outcomes is good news. However, there may be
several reasons for this finding. The patients from Tygerberg
Hospital are a highly selected group, which would tend to
minimise the effects of socioeconomic deprivation. In addition
because of the small donor pool in South Africa the majority of
patients receive poorly matched cadaver transplants regardless
of ethnicity.
The high mortality seen in women and in patients older than
40 years is a worrying problem and presents many challenges
to nephrologists. In most centres worldwide the two leading
causes of death are cardiovascular (CVS) complications and
infection. These findings are confirmed by Moosa. In his report
36.1% and 40% of deaths were due to CVS disease or infection
respectively.
It is often not recognised that patients with chronic renal
failure are at high risk of CVS complications even in the
absence of diabetes. It is now well established that an elevated
creatinine and/or albuminuria are powerful independent CVS
risk factors,13-15 and these parameters have been incorporated in
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the new European Hypertension Guidelines for CVS risk
stratification.16 This risk is probably due to a combination of
longstanding hypertension, lipid abnormalities, diabetes
mellitus and insulin resistance among other factors.
It is important to grasp that CVS disease is an important
preventable cause of death.  In general patients with renal
disease have a 10-year CVS risk greater than 30%.16 This
implies that primary prevention of CVS disease is cost effective
and the majority of patients should receive optimal blood
pressure  control (BP< 130/80 mmHg), statins to lower
cholesterol and antiplatelet drugs like aspirin. However, in the
state sector CVS therapy prevention is fraught with problems.
Statin therapy is available only to a minority with familial
hypercholesterolaemia and modern antihypertensive therapy is
often simply unobtainable. It seems penny wise pound foolish
to invest so much money, expertise and effort on dialysis and
transplantation, only for the patient to die of CVS com-
plications due to lack of availability of essential CVS drugs.
Policy decisions based on drug costs alone rather than overall
cost benefits seem to be rather short sighted.
Infection ranks with CVS disease as the other major cause of
death in patients with ESRD especially during the transplant
period due to the effects of immunosuppressive drugs. There is
clearly a fine balance due to under or over immunosuppre s s i o n ,
which may result in either rejection or susceptibility to
infection respectively. Moosa found that women and patients
older than 40 years had a higher mortality and suggests that
this may be in part due to changes in the pharmacokinetics and
dynamics in these groups. This is a reasonable hypothesis and
there is an important need to explore this issue in special
populations such as women and the elderly.
Death due to infection, like CVS disease, is also potentially
preventable. In transplant patients this is generally due to
opportunistic infections such as TB, Pneumocystis carinii
pneumonia (PCP), and cytomegalovirus infection (CMV). In
Moosa’s paper these infections were not a major problem. TB
or PCP caused only 9.7% and 5% of deaths due to infection
respectively.3 There were no reported cases of CMV infection.
These findings are consistent with their policy of giving
prophylaxis for TB, PCPand CMV. The majority of deaths were
due to lung infection and septicaemia. We are not given further
details of the exact causes of these infections and an important
weakness of this paper is the lack of postmortem findings in
these cases. It is the author’s experience that disseminated TB
or CMV may be an unexpected finding at postmortem
examination. Nevertheless, infection in transplant patients
should be seen as a life-threatening complication and
investigated and treated aggressively.
In conclusion, Moosa should be congratulated on carefully
documenting the outcomes of renal transplantation at
Tygerberg Hospital from 1976 to 1999. The important findings
in this paper are that outcome of renal transplantation in blacks
is the same as for other ethnic groups, but survival is worse in
women and patients older than 40 years. Graft survival was
good provided that it was censored for death. These findings
present important challenges to the practising nephrologist in
South Africa.
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